Imiquimod
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Imiquimod: From Actinic Keratosis and Genital Warts to Pre-malignant Neoplasm
One-Sentence Summary
Imiquimod is a topical immune response modifier originally used for skin conditions such as actinic keratosis, superficial basal cell carcinoma and anogenital warts. The TxGNN model predicts it may be effective for pre-malignant neoplasm, with 2 clinical trials and 9 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Common wart, anogenital HPV infection, superficial multifocal basal cell carcinoma, actinic keratosis and related skin conditions (the Singapore licence has no indication text on file) |
| Predicted New Indication | Pre-malignant neoplasm |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L1 (as assigned in the compiled data; see the note below) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Note on the evidence level: The L1 grade requires at least two completed Phase 3 RCTs. Only one of the two Phase 3 trials is completed (and it is a single-arm, open-label study with 20 participants). The other was a randomised trial terminated after 9 participants. A stricter reading would place the evidence closer to L2/L3, supported mainly by reviews and case reports. The decision below reflects this caution.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on general pharmacology, imiquimod is a Toll-like receptor 7 (TLR7) agonist. It induces local release of interferon-alpha, TNF-alpha and IL-12, which activates innate and adaptive immunity in the skin.
This immune activation is thought to help clear dysplastic and pre-malignant epithelial lesions. Imiquimod is already used for actinic keratosis, a classic pre-malignant skin lesion. The predicted indication is therefore a broadening of the original use to related pre-malignant lesions. The literature reports use in vulvar, anal, cervical and penile intraepithelial neoplasia, many of which are HPV-driven like the original wart indications.
Other predictions in the list (for example benign neoplasm of the buccal mucosa and odontogenic cyst) rest on preclinical work or indirect evidence. The remaining predictions (cervical neuroblastoma, nasopharyngeal teratoma, neoplasm of major salivary gland, schwannoma of jugular foramen) have no supporting studies. The pre-malignant neoplasm prediction is the only one with clinical trial data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00175643 | Phase 3 | Completed | 20 | Open-label, single-arm study of imiquimod 5% cream (3 days per week, 1 or 2 cycles) for actinic keratoses on the head; assessed duration of effect. Very small, supportive only. |
| NCT02329171 | Phase 3 | Terminated | 9 | Randomised trial of topical imiquimod for high-grade cervical intraepithelial neoplasia, as a less invasive alternative to excision. Stopped early with 9 participants, so no efficacy conclusion is possible. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23235673 | 2012 | Cochrane systematic review | Cochrane Database Syst Rev | Interventions for anal canal intraepithelial neoplasia, a pre-malignant HPV-associated condition |
| 21491403 | 2011 | Cochrane systematic review | Cochrane Database Syst Rev | Medical interventions for high-grade vulval intraepithelial neoplasia |
| 26516853 | 2015 | Review | Int J Mol Sci | Combined treatments with photodynamic therapy for non-melanoma skin cancer |
| 15584683 | 2004 | Review | Semin Cutan Med Surg | Topical strategies (fluorouracil, diclofenac, imiquimod, PDT) for non-melanoma skin cancer and precursor lesions |
| 20505896 | 2010 | Review | Skin Therapy Lett | Current management of actinic keratoses, including topical field therapy |
| 30284955 | 2019 | Case report | Int J STD AIDS | Successful imiquimod 5% treatment of high-grade vulval intra-epithelial neoplasia in a renal transplant recipient |
| 15601490 | 2004 | Case report | Int J STD AIDS | Clearance of penile bowenoid papulosis with imiquimod 5% cream |
| 29500135 | 2018 | Preclinical (rat) | Urol Oncol | Pharmacokinetics of TLR7 agonists (TMX-101, TMX-202) for bladder cancer; related compounds, not imiquimod itself |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN10105P | ALDARA CREAM 5% | Cream (topical) | Not stated in the compiled data |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): photoparoxysmal response, photosensitivity disease, autoimmune disease, graft versus host disease and sunburn. These come from a knowledge graph and should be checked against the official label.
- Drug Interactions: 59 potential interactions were identified in the interaction database, but none has a severity grade (all are "Unknown"). Examples include pantoprazole, omeprazole, morphine, prednisone, simvastatin, warfarin and clopidogrel. Given that imiquimod is applied topically, the clinical relevance of these entries needs verification.
- Reports from the literature: Malignant conversion of oral papillomatosis during imiquimod use, lichen planopilaris, erythema multiforme and a new mucinous carcinoma in extramammary Paget disease have been described in single case reports. Causality is unproven, but they warrant vigilance, especially for off-label use on mucosal sites.
Please refer to the package insert for the approved warnings and contraindications, as these were not available in the compiled data.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Imiquimod already has an established role in actinic keratosis, and the proposed use in pre-malignant lesions is mechanistically coherent and supported by reviews and case reports. However, the trial evidence is thin (one small single-arm completed trial and one terminated trial), so the evidence is weaker than the assigned L1 grade suggests.
To proceed, the following is needed:
- The HSA package insert, to confirm approved indications, warnings and contraindications (a blocking gap for safety screening)
- Verified mechanism of action data from DrugBank
- Adequately powered randomised trials in specific pre-malignant sites (for example cervical, vulvar or anal intraepithelial neoplasia)
- Grading of the unrated interaction entries, and a monitoring plan for patients with photosensitivity, autoimmune disease or immunosuppression
- Site-specific safety review before any mucosal or oral use, since the oral and other non-skin predictions are not supported by clinical data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.